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DermatomyositisAutoimmune diseases in pediatric patients are heteroge-
neous, including systemic lupus erythematosus, juvenile
rheumatoid arthritis, and juvenile dermatomyositis
(JDM).1,2 JDM is a rare autoimmune disease involving mul-
tiple body systems and accounts for 85% of idiopathic in-
flammatory myopathies in children. JDM may lead to death
or long-term disability; therefore, investigations into the
important prognostic factors for guiding the treatment of
JDM are crucial. However, to date, there is no standard
guideline for the treatment of JDM. In this issue, Sun et al3
report a 20-year retrospective analysis of treatment and
clinical outcomes to investigate outcomes of JDM in Taiwan
and to identify predictors or factors associated with out-
comes. The study gives us new insight into JDM.
JDM is an immune-mediated inflammatory disease
involving the microvasculature of skin and muscle. The most
common initial presentations are Gottron’s papules and
muscle weakness. The clinical features are associated with
systemic vasculopathy and are critical to the diagnosis.
However, recent studies have suggested that magnetic reso-
nance imaging is also useful in diagnosing JDM and that it may
be used as a disease assessment tool.4 A recent clinical study
showed that peripheral blood regulator T cells (Tregs) of
active JDMpatients were less capable of suppressing effector
T-cell activation in vitro compared with Tregs of JDM in clin-
ical remission.5 Therefore, the functional impairment of
Tregs plays an important role in JDM inflammation in a pro-
portion of patients with active disease.5 JDM is a heteroge-
neous disease and autoantibodies may be potentially useful
biomarkers to classify patients into homogeneous subgroups
and informon disease prognosis. Autoantibody status and age
atdiseaseonsethavealsobeen shownto influence theclinical
phenotype and overall prognosis in JDM.6 In JDM, the devel-
opment of calcinosis has been reported to be associated with
delayed diagnosis, a chronic disease course, and inade-
quately treated disease.7 Sun et al3 reported important
prognostic factors of JDM in children for predicting clinical
outcomes of such patients. Their findings suggest that calci-
nosis, skin ulcerations, and muscle weakness may develop
several years later during follow-up, because aggressivehttp://dx.doi.org/10.1016/j.pedneo.2014.10.001
1875-9572/Copyright ª 2014, Taiwan Pediatric Association. Published btreatment is suggested by some clinicians. The prognosis of
amyopathicDM,unlike that in adult groupswith the increased
risks of interstitial lung disease and malignancy, has a
generally good prognosis among pediatric patients.
There is no standard treatment protocol for JDM to date.
Since the introduction of corticosteroids to treat JDM, sig-
nificant improvements in clinical and functional prognosis
have been achieved, and therefore, they remain the main-
stay of treatment. However, systemic corticosteroids are
associated with significant side effects after long-term use.
Either immunosuppressive agents or intravenous immuno-
globulin is a supplemental therapy for JDMpatientswith poor
treatment responses. Biologic drugs, which are synthesized
within a biologic system, are designed to target specific
molecules involved in cytokine signaling or cellecell in-
teractions. The major targets of these biologic drugs are
cytokines, immune cells, and some costimulationmolecules.
The three classic inflammatory cytokines, namely, tumor
necrosis factor-a (TNF-a), interleukin-6 (IL-6), and IL-1, are
the major targets of biologic therapies. The major immune
cells targeted are B cells and T cells. In the past 2 decades,
biologic drugs have seena revolution in the rangeof effective
treatments for pediatric rheumatic diseases, particularly
juvenile idiopathic arthritis. As a result, minimal long-term
disease-associated damage is increasingly becoming
achievable. In the study by Sun et al,3 four patients received
etanercept, an anti-TNF agent. Two of these four patients
achieved complete clinical response after 15 months and 18
months of treatment, respectively (including etanercept and
corticosteroid); however, one of these patients later devel-
oped disease flares during follow-up and required cortico-
steroid control. The other two patients showed poor
response to anti-TNF agents and remain under multiple
medications. Treatment with anti-TNF agents may be
effective for adults with refractory DM or polymyositis, but
these were not promising in the current study of JDM.
This article by Sun et al3 covers many important aspects,
including prognostic factors and current treatment options for
JDM, which will surely provide a better understanding about
the role of various predictive factors in JDM. However, theiry Elsevier Taiwan LLC. All rights reserved.
2 Editorialcase numbers are still low. Large population and long-term
studies on JDM aimed at determining the prognostic factors
and treatment options, especially in severe cases, are still
needed.
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